23530-43-0

Basic information

• Product Name: N,N-dimethyl-2-nitrobenzenesulfonamide
• Synonyms: N,N-dimethyl-2-nitrobenzenesulfonamide
• CAS NO: 23530-43-0
• Molecular Formula: C₈H₁₀N₂O₄S
• Molecular Weight: 230.241
• EINECS: -0
• Mol File: 23530-43-0.mol
• Article Data: 15

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N,N-dimethyl-2-nitrobenzenesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-dimethyl-2-nitrobenzenesulfonamide(23530-43-0)
• EPA Substance Registry System: N,N-dimethyl-2-nitrobenzenesulfonamide(23530-43-0)

Safety Data

• Hazardous Substances Data: 23530-43-0(Hazardous Substances Data)

Upstream product

• 87-52-5 3-(Dimethylaminomethyl)indole 
• 1694-92-4 2-Nitrobenzenesulfonyl chloride 
• 506-59-2 N,N-dimethylammonium chloride 
• 124-40-3 dimethyl amine 

Downstream Products

• 54468-86-9 2-amino-N,N-dimethyl-benzenesulfonamide 
• 1022956-26-8 2-((2,5-dichloropyrimidin-4-yl)amino)-N,N-dimethylbenzenesulfonamide 
• 60287-57-2 1,3-dimethyl-5-(2-nitrophenoxy)benzene 
• 54106-40-0 1-methyl-2-(2-nitrophenoxy)benzene 
• 54495-62-4 2-(3'-methylphenoxy)nitrobenzene 
• 3402-70-8 1-nitro-2-(p-tolyloxy)benzene 
• 2216-12-8 1-nitro-2-phenoxy-benzene 
• 56966-62-2 1-(2-nitrophenoxy)-4-bromobenzene 
• 93974-08-4 1-fluoro-2- (2-nitrophenoxy)benzene 
• 4475-59-6 1-(4-fluorophenoxy)-2-nitrobenzene 
• 58656-16-9 2-(4-methoxyphenoxy)nitrobenzene 

Relevant articles and documents

AXL INHIBITOR FORMULATIONS

Formulations of Compound 1 or a pharmaceutically acceptable salt thereof are described. Also disclosed are capsules having a dry blended powder comprising Compound 1 or a pharmaceutically acceptable salt thereof. The Compound 1 or a pharmaceutically accep

AXL KINASE INHIBITORS AND USE OF THE SAME

Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrat

INHIBITORS OF CYCLIN DEPENDNT KINASE 7 (CDK7)

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases (e.g., cancers (e.g., leukemia, melanoma, multiple myeloma), benign neoplasms, angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of cyclin-dependent kinase 7 (CDK7), and therefore, induce cellular apoptosis and/or inhibit transcription in the subject.